Interesting to see NGIO’s Ii-key mentioned in a peer review although it wasn’t part of the paper’s research:
An alternative promising approach already successfully tested in clinical trials of cancer vaccines is the Ii-Key hybrid technology [141]. Ii-Key is a fragment of the Ii protein (or MHC class II-associated invariant chain), which physiologically binds to MHC-II molecules after synthesis, preventing binding to endogenous peptides. It is removed before binding of exogenous peptides. Ii-key binds all HLA-types with high affinity. Linking MHC-II-restricted epitopes to Ii-key enhances their potency to active CD4+ T cells and, most notably, does not require HLA matching, thereby enabling the use of a unique epitope for all individuals. However, this technology has not been used in atherosclerosis.
Vaccination in Atherosclerosis
by Felix Sebastian Nettersheim †, Lauren De Vore †OrcID and Holger Winkels *
Department III of Internal Medicine III, Heart Center, Faculty of Medicine and University Hospital of Cologne, 50937 Cologne, Germany
*
Author to whom correspondence should be addressed.
†
These authors contributed equally to this work.
Cells 2020, 9(12), 2560; https://doi.org/10.3390/cells9122560
Received: 9 November 2020 / Revised: 26 November 2020 / Accepted: 27 November 2020 / Published: 30 November 2020
https://www.mdpi.com/2073-4409/9/12/2560/htm
An alternative promising approach already successfully tested in clinical trials of cancer vaccines is the Ii-Key hybrid technology [141]. Ii-Key is a fragment of the Ii protein (or MHC class II-associated invariant chain), which physiologically binds to MHC-II molecules after synthesis, preventing binding to endogenous peptides. It is removed before binding of exogenous peptides. Ii-key binds all HLA-types with high affinity. Linking MHC-II-restricted epitopes to Ii-key enhances their potency to active CD4+ T cells and, most notably, does not require HLA matching, thereby enabling the use of a unique epitope for all individuals. However, this technology has not been used in atherosclerosis.
Vaccination in Atherosclerosis
by Felix Sebastian Nettersheim †, Lauren De Vore †OrcID and Holger Winkels *
Department III of Internal Medicine III, Heart Center, Faculty of Medicine and University Hospital of Cologne, 50937 Cologne, Germany
*
Author to whom correspondence should be addressed.
†
These authors contributed equally to this work.
Cells 2020, 9(12), 2560; https://doi.org/10.3390/cells9122560
Received: 9 November 2020 / Revised: 26 November 2020 / Accepted: 27 November 2020 / Published: 30 November 2020
https://www.mdpi.com/2073-4409/9/12/2560/htm
3
